news
Biotech firms push to exempt orphan drugs from price cuts
A coalition of biotech companies is lobbying the US government to exclude orphan drugs, which treat rare diseases, from new federal pilot programs designed to lower Medicare costs. They argue that price controls could stifle innovation for these critical, often life-saving, treatments. This move could impact access and affordability for patients relying on specialized therapies.
A coalition of biotech companies is lobbying the US government to exclude orphan drugs, which treat rare diseases, from new federal pilot programs designed to lower Medicare costs. They argue that price controls could stifle innovation for these critical, often life-saving, treatments. This move could impact access and affordability for patients relying on specialized therapies.
The architecture take
The drug industry is playing hardball on this one, trying to carve out an important exemption from Medicare's attempts to reel in drug prices. On one hand, rare disease drugs are ridiculously expensive and often life-changing, so companies argue they need high margins to justify the R&D. But on the other, this could leave a huge loophole for 'orphan' designations to get abused, letting drugmakers side-step price caps on what could be mass-market therapies down the line. It's a classic tension between innovation and affordability, where the nervous system benefits if fewer people are financially ruined by their prescriptions. Watch the fine print here; how 'rare' is rare enough? This sets a precedent for how every new biotech — from GLP-1s to psychedelics — eventually gets priced and regulated.